

# THE OPEN UNIVERSITY OF SRI LANKA FACULTY OF HEALTH SCIENCES DEPARTMENT OF MEDICAL LABORATORY SCIENCES ACADEMIC YEAR 2018/2019 – SEMESTER II




BACHELOR OF MEDICAL LABORATORY SCIENCES (BMLS) HONOURS MDU5401 – ADVANCED HEMATOLOGY – LEVEL 5 NBT I

| ,                                | DURATION: 1 HOUR AND 30 MINUTES |
|----------------------------------|---------------------------------|
| DATE: 15 <sup>TH</sup> JULY 2019 | TIME: 11.00 AM – 12.30 PM       |
|                                  |                                 |
| I                                | Registration No:                |

## IMPORTANT INSTRUCTIONS/INFORMATIONS TO CANDIDATES

- This question paper consists of 14 pages with 10 Multiple Choice Questions (Part A), 04 Structured Essay Questions (Part B) and 01 Essay Question (Part C).
- Write your Registration Number in the space provided.
- Answer ALL questions.
- Multiple Choice Questions (Part A): Indicate the best answer for each question in the answer sheet provided by placing a cross (X) in INK in the relevant cage. (Answers in pencil will NOT be marked)
- Structured Essay Questions (Part B): Write answers within the space provided.
- Essay Questions (Part C): Write answers in the given booklet.
- Do not remove any page/part of this question paper from the examination hall.
- Mobile phones and any other electronic equipment are NOT allowed. Leave them outside.



- 6) Myeloproliferative Neoplasms (MPNs) frequently consists of,
  - A) patients with JAK2 mutation negative and Philadelphia chromosome positive.
  - B) patients with JAK2 mutation negative and Philadelphia chromosome negative.
  - C) patients with JAK2 mutation positive and Philadelphia chromosome negative.
  - D) patients with JAK2 mutation positive and Philadelphia chromosome positive.

## 7) Immunophenotyping,

- A) is commonly used in the diagnosis of acute leukemia and its sub types.
- B) is commonly used in the diagnosis of chronic leukemia and its sub types.
- C) is commonly used in the diagnosis of multiple myeloma and its related disorders.
- D) is commonly used in the diagnosis of myeloproliferative neoplasms.

### 8) Immunomarkers such as CD 19, CD 20, CD 22 and CD 10

- A) are used in the diagnosis of malignancies in myeloid lineage.
- B) are used in the diagnosis of malignancies in granulocytic lineage.
- C) are used in the diagnosis of malignancies in lymphoid lineage.
- D) are used in the diagnosis of malignancies in erythroid lineage.

### 9) Acute myeloid leukemia (AML) and chronic myeloid leukemia (CML) are,

- A) common in both adults and children.
- B) less common in adults.
- C) less common in children.
- D) are always age dependent.

#### 10) Immunocompromising,

- A) can be associated with patients of multiple myeloma and chronic lymphatic leukemia (CLL).
- B) can be associated with patients of acute lymphoblastic leukemia (ALL) and chronic lymphatic leukemia (CLL).
- C) can be associated with patients of acute lymphoblastic leukemia (ALL) and multiple myeloma.
- D) can be associated with patients of acute myeloid leukemia (AML) and chronic lymphatic leukemia (CLL).

| 000   | 753 |
|-------|-----|
| 10 mm | A   |

Registration No:

# PART B – Structured Essay Questions

| 1. | Ear  | ly screening of leukemic conditions in patients those who attend base hospital   |  |  |  |  |  |  |
|----|------|--|--|--|--|--|--|--|
|    | clin | clinics is an absolute need today as the delay may cause progressing of the disease. In the laboratory, total white cell count (WBC) and platelet count play a pivotal role in |  |  |  |  |  |  |
|    | the  |  |  |  |  |  |  |  |
|    | the  | screening of leukemia conditions.  |  |  |  |  |  |  |
|    | 1.1. | Name two (02) other hematological investigations that could use to screen leukemic   |  |  |  |  |  |  |
|    |      | conditions in the laboratory. (10 marks)   |  |  |  |  |  |  |
|    | I.   |  |  |  |  |  |  |  |
|    | II.  |  |  |  |  |  |  |  |
|    | 1.2. | Explain how total WBC and platelet count contribute to screen acute leukemia in the  |  |  |  |  |  |  |
|    |      | laboratory. (20 marks)   |  |  |  |  |  |  |
|    |      |  |  |  |  |  |  |  |
|    |      |  |  |  |  |  |  |  |
|    |      |  |  |  |  |  |  |  |
| -  |      |  |  |  |  |  |  |  |
|    |      |  |  |  |  |  |  |  |
|    | 1.3. | How do you use peripheral blood white cell cytomorphology to screen acute myeloid  |  |  |  |  |  |  |
|    |      | leukemia (AML)? (20 marks)   |  |  |  |  |  |  |
|    |      | ·  |  |  |  |  |  |  |
|    |      |  |  |  |  |  |  |  |
|    |      |  |  |  |  |  |  |  |
|    |      |  |  |  |  |  |  |  |
|    |      |  |  |  |  |  |  |  |
|    |      |  |  |  |  |  |  |  |
|    |      |  |  |  |  |  |  |  |
|    |      | ·  |  |  |  |  |  |  |
|    |      |  |  |  |  |  |  |  |

|      | Registration No:  |
|------|---|
| 1.4. | List five (05) special laboratory investigations that are used to confirm the diagnosis |
| ;    | as AML. (30 marks)  |
|      |   |
| I.   |   |
| Π.   |   |
| III. |   |
| IV.  |   |
| V.   |   |
|      |   |
|      | Describe the expected major findings of one (01) investigation that you mentioned in    |
|      | 4. (20 marks)   |
|      |   |
| . ·  |   |
|      |   |
|      |   |
|      |   |
|      |   |
|      |   |
| •    |   |
| •    |   |
|      |   |
|      |   |
|      |   |
|      |   |
|      |   |
|      |   |
| (7   | Total: 20 marks)  |

| pains. His further investigations revealed hepatosplenomegally. Results of few of the laboratory investigations are as follows. |                                  |   |  |
|---|----------------------------------|---|--|
| ~ ~   | ne marrow myelogram show         |   |  |
| Neutrophils-35% Basophils-02%.  |                                  | Eosinophils-03%, Monocytes-03%,                 |  |
| 2.1. Giving reason  | ons state the most probable dise | ease or condition. (50 marks)                   |  |
|   |                                  |   |  |
| 2.2. Suggest the v  | white cell abnormalities that m  | nay present in the peripheral blood. (20 marks) |  |
|   |                                  |   |  |

00053

|      | Registration   | on No:                                  |
|------|--|---|
| 2.3. | 3. Name one (01) other disease or condition that may asso- | ciate with similar laboratory           |
|      | findings.  | (5 marks)                               |
|      |  |   |
|      |  |   |
| 2.4. | 4. How do you differentiate the diseases or conditions men | tioned in 2.1 & 2.3?                    |
|      |  | (25 marks)                              |
|      |  |   |
|      | ••••••   |   |
|      |  |   |
|      |  | •••••                                   |
|      |  | ••••••                                  |
|      |  | *************************************** |
|      |  |   |
|      |  |   |
|      |  |   |

3. An analyzer report that obtained from 10 years old boy who is clinically suspected as leukemia and also presents with mild bleeding gums is shown. According to the findings of the report, his WBC shows marked increased with high absolute lymphocyte count & neutrophil count.

| Test requested                           | Results            |   | Reference range | Units        |              |     |
|--|--------------------|---|-----------------|--------------|--------------|-----|
| Reticulocyte count                       |                    |   |                 |              |              |     |
| Reticulocyte count total                 | 2.1 (HIGH)         |   | 0 - 1           | %            |              |     |
| Absolute reticulocyte                    | 33,600             |   | <60,000         | /μL          |              |     |
| Complete blood count                     |                    |   |                 |              |              |     |
| WBC                                      | 304.0 (HIGH) 🦃     |   | 4.0 - 15.5      | $10^3/\mu L$ |              |     |
| RBC                                      | 1.8 (LOW)          |   | 4.6 - 9.3       | $10^3/\mu L$ |              |     |
| HGB                                      | 3.1 (LOW)          |   | 12.1 - 20.3     | g/dL         |              |     |
| HCT                                      | 11 (LOW)           |   | 38 - 60         | %            |              |     |
| MCV                                      | 71                 |   | 58 – 79         | fL           |              |     |
| МСН                                      | 19.5               |   | -19 - 28        | pg           |              |     |
| MCHC                                     | 28 (LOW)           |   | 30 - 38         | %            |              |     |
| Comment                                  |                    |   |                 |              |              |     |
| POLYCHROMASIA +1                         |                    |   |                 |              |              |     |
| HYPOCHROMASIA +3                         |                    |   |                 |              |              |     |
| NRBC                                     | 1                  |   | 0-1             | /100 WBC     |              |     |
| Differential                             | Absolute           | % |                 |              |              |     |
| Neutrophils                              | 12160 (HIGH) 4     |   | 12160 (HIGH) 4  |              | 2060 - 10600 | /μL |
| Lymphocytes                              | 285760 (HIGH) 94 🕊 |   | 690 – 4500      | /µL          |              |     |
| Monocytes                                | 6080 (HIGH) 2      |   | 0 - 840         | /μL          |              |     |
| Platelet estimation                      |                    |   |                 |              |              |     |
| Platelet appear decreased on blood smear |                    |   |                 |              |              |     |

| 3.1 | Would   | you    | accept  | the    | result | s of   | absol   | lute     | lymp  | hocy    | te cou            | nt wit     | h the | WBC   | count  |
|-----|---------|--------|---------|--------|--------|--------|---------|----------|-------|---------|-------------------|------------|-------|-------|--------|
|     | accordi | ing to | the cli | inical | featu  | res of | f the p | oatie    | nt? C | live re | asons.            |            |       | (40 n | narks) |
|     |         |        |         |        |        |        |         |          |       |         |                   |            |       |       |        |
|     |         |        |         |        |        |        |         | <i></i>  |       |         | <i>.</i>          |            |       |       |        |
|     |         |        |         |        |        |        |         | <i>.</i> |       |         | • • • • • • • • • | . <i>.</i> |       |       |        |
|     |         |        |         |        |        |        |         |          |       |         |                   |            |       |       |        |
|     |         |        |         |        |        |        |         |          |       |         |                   |            |       |       |        |
|     |         |        |         |        |        |        |         |          |       |         |                   |            |       |       |        |
|     |         |        |         |        |        |        |         |          |       |         |                   | , . , ,    |       |       |        |
|     |         |        |         |        |        |        |         |          |       |         |                   |            |       |       |        |
|     |         |        |         |        |        |        |         | ,.,      |       |         |                   | <i>.</i>   |       |       |        |
|     |         |        |         |        |        |        |         |          |       |         | •                 | <i>.</i>   |       |       |        |
|     |         |        |         |        |        |        |         |          |       |         |                   |            |       |       |        |

|            | Registration No:   |
|------------|--|
| 3.2 Simila | ar findings were obtained from the repeated analysis of the sample using the |
| same       | analyzer and also with the fresh blood sample of the same patient.           |
|            |  |
| 3.2.1      | What laboratory test you would perform immediately to accept or reject the   |
|            | results mentioned in 3.1? Describe the expected results. (20 marks)          |
|            |  |
|            | · · · · · · · · · · · · · · · · · · ·  |
|            |  |
|            |  |
|            |  |
|            |  |
|            |  |
|            |  |
|            |  |
|            |  |
|            |  |
| 3.2.2      | Name four (04) other special investigations that could use to establish the  |
|            | diagnosis according to the clinical findings. (20 marks)                     |
|            | (20 million)   |
| ĭ          |  |
|            |  |
|            |  |
| Ш          |  |
| IV         |  |
|            |  |
| 3.2.3      | Describe the expected major findings of one (01) investigation that you      |
|            | mentioned in 3.2.2. (20 marks)   |
|            |  |
|            |  |
| ******     |  |
| ******     |  |
|            |  |
| ,,,,,,,    |  |
|            |  |
| ******     |  |
| *******    |  |

| Name four (04) type of myeloma and name the most frequent      | type. (25 marks                         |
|--|---|
| I  |   |
| I  |   |
| I  |   |
| /  | · · · · · · · · · · · · · · · · · · ·   |
| 2 Describe the role of plasma cells in multiple myeloma.       | (30 marks                               |
|  |   |
| ·  | • |
|  |   |
|  |   |
|  | • |
|  |   |
|  |   |
|  |   |
|  |   |
|  |   |
|  | • |
|  |   |
|  |   |
|  |   |
| Name three (03) laboratory findings used in the diagnosis of m | ultiple myeloma.                        |
|  | (15 marks)                              |
| I  |   |

|             | Registration No:   | • • • |
|-------------|--|-------|
| 4.4         | Describe the expected major findings of the investigations that you mentioned in |       |
|             | 4.3. (30 mark  | :s)   |
| ••••        |  |       |
|             |  |       |
|             |  |       |
|             |  | •••   |
|             |  |       |
|             |  |       |
| • • • • • • |  |       |
|             |  |       |
|             |  |       |
| • • • • •   |  |       |
|             |  |       |
|             |  |       |
|             |  |       |
|             |  |       |
|             |  |       |
|             |  |       |
|             |  |       |

(Total: 100 marks)

Page 12 of 14

# PART C - Essay Question

- 1) Explain the pathological basis of the followings
  - 1.1 Appearance of late normoblasts in the peripheral blood of chronic myeloid leukemia (CML). (30 marks)
  - 1.2 Presence of paraproteins in the blood in multiple myeloma. (40 marks)
  - 1.3 Anemia in chronic lymphocytic leukemia B cell type (B-CLL). (30 marks)

\*\*\*\*\* Copyrights reserved \*\*\*\*\*

| D:                   | stration | ЪΤ   |
|----------------------|----------|------|
| $\kappa \rho \sigma$ | stration | INO. |
| 1000                 | ouuuu    |      |

# BACHELOR OF MEDICAL LABORATORY SCIENCES (BMLS) HONOURS MDU5401 – ADVANCED HEMATOLOGY – LEVEL 5 NBT I

| THE OYOUNG LONG DATE OF |            |
|-------------------------|------------|
| <b>REGISTRATION NO:</b> | ********** |

# ANSWER SHEET FOR PART A

| Q. No. | (A) | (B) | (C)                                      | (D) |
|--------|-----|-----|--|-----|
| 1      |     |     |  |     |
| 2      |     |     |  |     |
| 3      |     |     |  |     |
| 4      |     |     |  |     |
| 5      |     |     |  |     |
| 6      |     |     | ,  |     |
| 7      |     |     |  |     |
| 8      |     |     | ,a # * * * * * * * * * * * * * * * * * * |     |
| 9      | z   |     |  |     |
| 10     |     |     |  |     |

\*\*\*\*\* Copyrights reserved \*\*\*\*\*